{"disease":{"id":"candidemia","name":"Candidemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":8,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"voriconazole","indication_name":"Candidemia in non-neutropenic patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"voriconazole","indication_name":"Candidemia in Non-neutropenic Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"caspofungin","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cancidas","generic_name":"CASPOFUNGIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":63,"revenue":null,"mechanism":"Cancidas works by inhibiting the synthesis of beta-1,6-glucan, a critical component of the fungal cell wall."},{"drug_id":"anidulafungin","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eraxis","generic_name":"ANIDULAFUNGIN","company_name":"Vicuron Holdings","drug_phase":"marketed","molecular_target":"","drug_class":"Echinocandin Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":"Eraxis works by inhibiting the synthesis of beta-1,3-D-glucan, a critical component of the fungal cell wall."},{"drug_id":"micafungin","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycamine","generic_name":"MICAFUNGIN","company_name":"Teva Pharms Usa Inc","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"itraconazole","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazol","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluconazol","company_name":"Azienda Sanitaria-Universitaria Integrata di Udine","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia and Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":43,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04368559","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":602,"lead_sponsor_name":"Mundipharma Research Limited","has_results":false},{"nct_id":"NCT00413218","title":"Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT05421858","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Basilea Pharmaceutica","has_results":false},{"nct_id":"NCT06859671","title":"A Randomized Study of a Short Duration Therapy for Candidemia","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":362,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07272915","title":"Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI)","phase":"","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT00802854","title":"Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV","phase":"","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04147975","title":"Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":225,"lead_sponsor_name":"HelixBind, Inc.","has_results":false},{"nct_id":"NCT04979052","title":"Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT03667690","title":"Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT06907992","title":"A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Augusta University","has_results":false},{"nct_id":"NCT00608335","title":"Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03799172","title":"Echinocandins Versus Azoles for Candidemia Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05178862","title":"A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":68,"lead_sponsor_name":"Scynexis, Inc.","has_results":false},{"nct_id":"NCT01982071","title":"A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":59,"lead_sponsor_name":"Astellas Pharma China, Inc.","has_results":false},{"nct_id":"NCT05385107","title":"Value of PCT When Diagnosing Candidemia","phase":"","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT03363841","title":"Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT03604705","title":"An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Basilea Pharmaceutica","has_results":true},{"nct_id":"NCT04148287","title":"An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Basilea Pharmaceutica","has_results":true}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}